Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Y0000521

Nevirapine for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Nevirapine, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H14N4O
CAS Number:
129618-40-2
Molecular Weight:
266.30
MDL number:
MFCD00866928
UNSPSC Code:
41116107
PubChem Substance ID:
329831002
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nevirapine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC1=CC=NC2=C1NC(C(C=CC=N3)=C3N2C4CC4)=O

InChI

1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)

InChI key

NQDJXKOVJZTUJA-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nevirapine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

NNRTI (non-nucleoside reverse transcriptase inhibitor) of HIV-1
Nevirapine is an allosteric, non-nucleoside inhibitor of HIV reverse transcriptase (NNRTI). The Ki for inhibition of wild-type RT by Nevirapine is 200 nM.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000520

Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard

Y0001499

Nevirapine hemihydrate, European Pharmacopoeia (EP) Reference Standard

1460703

Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard

1460714

Nevirapine hemihydrate, United States Pharmacopeia (USP) Reference Standard

1460725

Nevirapine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1460736

Nevirapine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1460747

Nevirapine Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1757

Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1760

Nevirapine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1761

Nevirapine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1762

Nevirapine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

E V Kazennova
Voprosy virusologii, 54(1), 45-48 (2009-03-04)
The review presents data on the use of a single prophylactic dose of nevirapine at labor given to a mother at the onset of labor in HIV-infected women and neonatal infants within 72 hours after birth in the absence of
Jean-Jacques Parienti et al.
Expert opinion on drug metabolism & toxicology, 7(4), 495-503 (2011-03-23)
Nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor, has been an important component of HIV infection treatment for many years. Currently, twice-a-day dosing is required for the successful application of NVP immediate release (IR), but there is potential for a more
Meenakshi Bendle et al.
The Journal of the Association of Physicians of India, 60, 39-44 (2013-06-21)
In India, parent to child transmission is the most important source of HIV infection in children below fifteen years of age. Transmission of HIV from mother to child can occur even at low or undetectable HIV virus levels. CD4 count
M Popovic et al.
Handbook of experimental pharmacology, (196)(196), 437-451 (2009-12-19)
Treatment of HIV-1 infections with nevirapine is associated with skin and liver toxicity. These two organ toxicities range from mild to severe, in rare cases resulting in life-threatening liver failure or toxic epidermal necrolysis. The study of the mechanistic steps
José Medrano et al.
AIDS reviews, 10(2), 110-115 (2008-07-11)
Implementation of combination antiretroviral therapies has transformed the prognosis of HIV infection during the past decade. Because of its low-pill burden, convenient administration once or twice daily without food restrictions and, in the case of nevirapine, favorable metabolic profile and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service